Substituted diarylureas, pharmaceutical compositions containing them, and their use for stimulating Fas-mediated apoptosis. The compounds, as single stereoisomers or mixtures of stereoisomers, their pharmaceutically acceptable salts, and pharmaceutical compositions containing them, are useful in methods of treating autoimmune diseases, infectious diseases, and malignancies.
Benzene Tricarboxylic Acid Derivatives As Insulin Receptor Activators
Compounds of Formula I, and pharmaceutical compositions containing these compounds, activate the insulin receptor kinase, which leads to an increased sensitivity to insulin and an increase in glucose uptake, and are therefore useful for the treatment of animals, especially humans, with hyperglycemia, especially for the treatment of type 2 diabetes. Processes for preparation of the compounds, and their use in assays, are also disclosed.
Antagonists Of Mcp-1 Function And Methods Of Use Thereof
Edgardo Laborde - Foster City CA Louise Robinson - San Carlos CA Fanying Meng - San Francisco CA Brian T. Peterson - San Francisco CA Hugo O. Villar - La Jolla CA Steven E. Anuskiewicz - San Bruno CA Yoshiro Ishiwata - Aichi-gun, JP Shoji Yokochi - Inabe-gun, JP Yukiharu Matsumoto - Gifu, JP Takuji Kakigami - Inabe-gun, JP Hideaki Inagaki - Anjoh, JP Takahito Jomori - Nagoya, JP Kouji Matsushima - Matsudo, JP
Assignee:
Telik, Inc. - Palo Alto CA Sanwa Kagaku Kenkyusho Co., Ltd. - Nagoya
The present invention relates to chemical compounds, pharmaceutical compositions comprising said compounds, uses of said compounds and compositions, methods of treatment employing said compounds and compositions, and processes for preparing said compounds. Specifically, this invention relates to novel compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohns disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection. More specifically, the invention is related to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases.
Antagonists Of Mcp-1 Function And Methods Of Use Thereof
Edgardo Laborde - Foster City CA Louise Robinson - San Carlos CA Fanying Meng - San Francisco CA Brian T. Peterson - San Francisco CA Hugo O. Villar - La Jolla CA Steven E. Anuskiewicz - San Bruno CA Yoshiro Ishiwata - Aichi-gun, JP Shoji Yokochi - Inabe-gun, JP Yukiharu Matsumoto - Gifu, JP Takuji Kakigami - Inabe-gun, JP Hideaki Inagaki - Anjoh, JP Takahito Jomori - Nagoya, JP Kouji Matsushima - Matsudo, JP
Assignee:
Telik, Inc. - Palo Alto CA Sanwa Kagaku Kenkyusho Co., Ltd.
Chemical compounds which are antagonists of Monocyte Chemoattractant Protein-1 (MCP-1) function, pharmaceutical compositions comprising these compounds, methods of treatment employing these compounds and compositions, and processes for preparing these compounds. The compounds are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohns disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection.
Antagonists Of Mcp-1 Function And Methods Of Use Thereof
Edgardo Laborde - Foster City CA Louise Robinson - San Carlos CA Fanying Meng - San Francisco CA Brian T. Peterson - San Francisco CA Hugo O. Villar - La Jolla CA Steven E. Anuskiewicz - San Bruno CA Yoshiro Ishiwata - Aichi-gun, JP Shoji Yokochi - Inabe-gun, JP Yukiharu Matsumoto - Gifu, JP Takuji Kakigami - Inabe-gun, JP Hideaki Inagaki - Anjoh, JP Takahito Jomori - Nagoya, JP Kouji Matsushima - Matsudo, JP
Assignee:
Telik, Inc. - Palo Alto CA Sanwa Kagaku Kenkyusho Co. - Nagoya
Compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohns disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection; pharmaceutical compositions comprising these compounds; and the use of these compounds and compositions in the prevention or treatment of such diseases.
Antagonist Of Mcp-1 Function, And Compositions And Methods Of Use Thereof
Edgardo Laborde - Foster City CA, US Louise Robinson - San Carlos CA, US Fanying Meng - San Francisco CA, US Brian T. Peterson - Mountain View CA, US Hugo O. Villar - La Jolla CA, US Steven E. Anuskiewicz - San Bruno CA, US Wenli Ma - Mountain View CA, US Yukiharu Matsumoto - Gifu, JP Kunihisa Baba - Yokkaichi, JP Hideaki Inagaki - Inabe, JP Katsumasa Tanaka - Inabe, JP Yoshiro Ishiwata - Aichi-gun, JP Shoji Yokochi - Inabe-gun, JP Masayuki Okamoto - Tokyo-to, JP Takashi Nakamura - Kuwana, JP Atsushi Miyachi - Kuwana, JP Mitsuaki Takeuchi - Inabe, JP Kouji Matsushima - Matsudo, JP
Assignee:
Telik, Inc. - Palo Alto CA Sanwa Kagaku Kenkyusho Co., Ltd. - Nagoya
Compounds of formula A and formula B: and their pharmaceutically acceptable salts, compositions comprising them, methods for their use, and their use in the preparation of medicaments. The compounds are antagonists of MCP-1 function, and are useful in the prevention and treatment of chronic or acute inflammatory or autoimmune diseases, such as multiple sclerosis, and in the prevention and treatment of allergic hypersensitivity disorders.
Antagonists Of Mcp-1 Function And Methods Of Use Thereof
Edgardo Laborde - Foster City CA, US Louise Robinson - San Carlos CA, US Fanying Meng - San Francisco CA, US Brian T. Peterson - San Francisco CA, US Hugo O. Villar - La Jolla CA, US Steven E. Anuskiewicz - San Bruno CA, US Yoshiro Ishiwata - Aichi-gun, JP Shoji Yokochi - Inabe-gun, JP Yukiharu Matsumoto - Gifu, JP Takuji Kakigami - Inabe-gun, JP Hideaki Inagaki - Anjoh, JP Takahito Jomori - Nagoya, JP Kouji Matsushima - Matsudo, JP
The present invention relates to chemical compounds, pharmaceutical compositions comprising said compounds, uses of said compounds and compositions, methods of treatment employing said compounds and compositions, and processes for preparing said compounds. Specifically, this invention relates to novel compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection. More specifically, the invention is related to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases.
Antagonists Of Mcp-1 Function And Methods Of Use Thereof
Edgardo Laborde - Foster City CA, US Louise Robinson - San Carlos CA, US Fanying Meng - San Francisco CA, US Brian T. Peterson - San Francisco CA, US Hugo O. Villar - La Jolla CA, US Steven E. Anuskiewicz - San Bruno CA, US Yoshiro Ishiwata - Aichi-gun, JP Shoji Yokochi - Inabe-gun, JP Yukiharu Matsumoto - Gifu, JP Takuji Kakigami - Inabe-gun, JP Hideaki Inagaki - Anjoh, JP Takahito Jomori - Nagoya, JP Kouji Matsushima - Matsudo, JP
Assignee:
Telik, Inc. - Palo Alto CA Sanwa Kagaku Kenkyusho Co. Ltd. - Nagoya
Chemical compounds which are antagonists of Monocyte Chemoattractant Protein-1 (MCP-1) function, pharmaceutical compositions comprising these compounds, methods of treatment employing these compounds and compositions, and processes for preparing these compounds. The compounds are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection.